|
1
|
Wohlmuth C, Wohlmuth-Wieser I and
Laframboise S: Clinical characteristics and treatment response with
checkpoint inhibitors in malignant melanoma of the vulva and
vagina. J Low Genit Tract Dis. 25:146–151. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wohlmuth C, Wohlmuth-Wieser I, May T,
Vicus D, Gien LT and Laframboise S: Malignant melanoma of the vulva
and vagina: A US population-based study of 1863 patients. Am J Clin
Dermatol. 21:285–295. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu Y, Tse KY, Lee HHY, Chow KL, Tsang HW,
Wong RWC, Cheung ETY, Cheuk W, Lee VWK, Chan WK, et al: Predictive
biomarkers and tumor microenvironment in female genital melanomas:
A multi-institutional study of 55 cases. Mod Pathol. 33:138–152.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wohlmuth C and Wohlmuth-Wieser I: Vulvar
malignancies: An interdisciplinary perspective. J Dtsch Dermatol
Ges. 17:1257–1276. 2019. View Article : Google Scholar
|
|
5
|
Slominski RM, Sarna T, Plonka PM, Raman C,
Brozyna AA and Slominski AT: Melanoma, melanin, and melanogenesis:
The yin and yang relationship. Front Oncol. 12:8424962022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garbe C, Amaral T, Peris K, Hauschild A,
Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B,
Fargnoli MC, et al: European consensus-based interdisciplinary
guideline for melanoma. Part 2: Treatment-update 2019. Eur J
Cancer. 126:159–177. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garbe C, Amaral T, Peris K, Hauschild A,
Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B,
Fargnoli MC, et al: European consensus-based interdisciplinary
guideline for melanoma. Part 1: Diagnostics-update 2019. Eur J
Cancer. 126:141–158. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strojan P: Role of radiotherapy in
melanoma management. Radiol Oncol. 44:1–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Komatsu-Fujii T, Nomura M, Otsuka A,
Ishida Y, Doi K, Matsumoto S, Muto M and Kabashima K: Response to
imatinib in vaginal melanoma with KIT p.Val559Gly mutation
previously treated with nivolumab, pembrolizumab and ipilimumab. J
Dermatol. 46:e203–e204. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anko M, Nakamura M, Kobayashi Y, Tsuji K,
Nakada S, Nakamura Y, Funakoshi T, Banno K and Aoki D: Primary
malignant melanoma of the uterine cervix or vagina which were
successfully treated with nivolumab. J Obstet Gynaecol Res.
46:190–195. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin L, Xue J, Li R, Zhou L, Deng L, Chen
L, Zhang Y, Li Y, Zhang X, Xiu W, et al: Effect of low-dose
radiation therapy on abscopal responses to hypofractionated
radiation therapy and anti-PD1 in mice and patients with non-small
cell lung cancer. Int J Radiat Oncol Biol Phys. 108:212–224. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohamad O, Diaz de Leon A, Schroeder S,
Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB,
Laine A, et al: Safety and efficacy of concurrent immune checkpoint
inhibitors and hypofractionated body radiotherapy. Oncoimmunology.
7:e14401682018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi J and Nagasawa S:
Immunostimulatory effects of radiotherapy for local and systemic
control of melanoma: A review. Int J Mol Sci. 21:93242020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gershenwald JE, Scolyer RA, Hess KR,
Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM,
McArthur GA, et al: Melanoma staging: Evidence-based changes in the
American joint committee on cancer eighth edition cancer staging
manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaffney DK, King B, Viswanathan AN,
Barkati M, Beriwal S, Eifel P, Erickson B, Fyles A, Goulart J,
Harkenrider M, et al: Consensus recommendations for radiation
therapy contouring and treatment of vulvar carcinoma. Int J Radiat
Oncol Biol Phys. 95:1191–1200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rao YJ, Chundury A, Schwarz JK,
Hassanzadeh C, DeWees T, Mullen D, Powell MA, Mutch DG and Grigsby
PW: Intensity modulated radiation therapy for squamous cell
carcinoma of the vulva: Treatment technique and outcomes. Adv
Radiat Oncol. 2:148–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Indini A, Di Guardo L, Cimminiello C,
Lorusso D, Raspagliesi F and Del Vecchio M: Investigating the role
of immunotherapy in advanced/recurrent female genital tract
melanoma: A preliminary experience. J Gynecol Oncol. 30:e942019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bence C, Hofman V, Chamorey E, Long-Mira
E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A,
Montaudié H, et al: Association of combined PD-L1 expression and
tumour-infiltrating lymphocyte features with survival and treatment
outcomes in patients with metastatic melanoma. J Eur Acad Dermatol
Venereol. 34:984–994. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Theelen WSME, Chen D, Verma V, Hobbs BP,
Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot
PM, et al: Pembrolizumab with or without radiotherapy for
metastatic non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Respir Med. 9:467–475. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang AC, Postow MA, Orlowski RJ, Mick R,
Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell
invigoration to tumour burden ratio associated with anti-PD-1
response. Nature. 545:60–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Welsh J, Menon H, Chen D, Verma V, Tang C,
Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, et al:
Pembrolizumab with or without radiation therapy for metastatic
non-small cell lung cancer: A randomized phase I/II trial. J
Immunother Cancer. 8:e0010012020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Quéreux G, Wylomanski S, Bouquin R,
Saint-Jean M, Peuvrel L, Knol AC, Hanf M and Dréno B: Are
checkpoint inhibitors a valuable option for metastatic or
unresectable vulvar and vaginal melanomas? J Eur Acad Dermatol
Venereol. 32:e39–e40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Theelen WSME, Peulen HMU, Lalezari F, van
der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I,
Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after
stereotactic body radiotherapy vs pembrolizumab alone on tumor
response in patients with advanced non-small cell lung cancer:
Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA
Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pierini S, Mishra A, Perales-Linares R,
Uribe-Herranz M, Beghi S, Giglio A, Pustylnikov S, Costabile F,
Rafail S, Amici A, et al: Combination of vasculature targeting,
hypofractionated radiotherapy, and immune checkpoint inhibitor
elicits potent antitumor immune response and blocks tumor
progression. J Immunother Cancer. 9:e0016362021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Escorcia FE, Postow MA and Barker CA:
Radiotherapy and immune checkpoint blockade for melanoma: A
promising combinatorial strategy in need of further investigation.
Cancer J. 23:32–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shabason JE and Minn AJ: Radiation and
immune checkpoint blockade: From bench to clinic. Semin Radiat
Oncol. 27:289–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yin G, Guo W, Huang Z and Chen X: Efficacy
of radiotherapy combined with immune checkpoint inhibitors in
patients with melanoma: A systemic review and meta-analysis.
Melanoma Res. 32:71–78. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barker CA, Postow MA, Kronenberg SA, Ma Y,
Yamada Y, Beal K, Chan TA, Callahan MK and Wolchok JD: Concurrent
radiation therapy (RT), ipilimumab (Ipi) and/or nivolumab (Nivo) on
a phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 93
(Suppl):S210–S211. 2015. View Article : Google Scholar
|
|
30
|
Ahmed KA, Stallworth DG, Kim Y, Johnstone
PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS and Gibney
GT: Clinical outcomes of melanoma brain metastases treated with
stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 27:434–41.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parisi S, Lillo S, Cacciola A,
Santacaterina A, Palazzolo C, Platania A, Settineri N, Franchina T,
Tamburella C and Pergolizzi S: Vaginal mucosal melanoma: A complete
remission after immunotherapy and '0-7-21'
radiotherapy regimen (24 Gy/3 fractions/21 days). Folia Med
(Plovdiv). 62:605–609. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schonewolf CA, Jaworski EM, Allen SG,
McLean K, Lao CD, Schuchter LM, Tanyi J and Taunk NK: Complete
response after stereotactic body radiation therapy with concurrent
immunotherapy for vaginal melanoma. Adv Radiat Oncol. 7:1008392021.
View Article : Google Scholar : PubMed/NCBI
|
